## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($62.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Olukotun of Arrowhead Pharma sells $676k in stock**
- Source: Investing.com | 20251223T230905 | Somewhat-Bullish | Relevance: 100%
- Adeoye Olukotun, Director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 10,000 shares of common stock for a total of $676,623 in December 2025. These sales were executed under a pre-arranged 10b5-1 trading plan, with prices ranging from $66.7 to $68.48. Following these transactions, Olukotun directly owns 33,600 shares, and the stock has shown strong momentum, up 249% over the past year.

**2. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells $566,027.55 in Stock**
- Source: MarketBeat | 20251223T000905 | Somewhat-Bearish | Relevance: 100%
- Arrowhead Pharmaceuticals Director William Waddill sold 8,367 shares of ARWR stock for a total of $566,027.55, reducing his direct ownership by 12.89%. Despite this insider selling, the stock has recently traded higher, and institutional investors hold a significant portion of its shares. Analysts maintain a "Moderate Buy" rating with an average target price of $61.89, with some firms raising their price targets.

**3. 76,408 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by HBK Sorce Advisory LLC**
- Source: MarketBeat | 20251224T110905 | Somewhat-Bullish | Relevance: 100%
- HBK Sorce Advisory LLC acquired 76,408 shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in Q3, valued at approximately $2.82 million, representing about 0.06% of the company. Despite recent insider selling, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and upcoming catalysts including a KOL webinar and a presentation at the J.P. Morgan Healthcare Conference in January. The company's stock shows strong financial metrics and has seen significant price performance over the last year.

**4. Arrowhead Pharma director Waddill sells $566k in stock**
- Source: Investing.com | 20251223T230905 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) director William D. Waddill sold 8,367 shares of common stock for a total of $566,038 on December 19, 2025. The sales were executed under a pre-arranged 10b5-1 trading plan, and Waddill continues to directly own 56,563 shares. The company has shown strong financial health and significant stock performance, with the stock currently trading at $69.83, near its 52-week high.

**5. First Week of February 2026 Options Trading For Arrowhead Pharmaceuticals (ARWR)**
- Source: Nasdaq | 20251223T170905 | Somewhat-Bullish | Relevance: 100%
- New options contracts for Arrowhead Pharmaceuticals (ARWR) with a February 2026 expiration have started trading. BNK Invest's YieldBoost formula highlights a put contract at a $67.50 strike price and a call contract at a $70.00 strike price, detailing potential returns for investors utilizing these options strategies.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Insider selling cluster: $3.7M in recent transactions.
2. Elevated short interest (11.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 6 raises (avg +31%) could attract flows.
- Momentum building: MRS_10 improving +1.2% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -31% YoY, concerning. Analyst sentiment positive (6 raises, avg +31%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 0.0% to 1.2% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.21% (CS: 88) | Neutral |
| RSI_14 | 69.9 | Neutral |
| MACD Histogram | -0.49 | Bearish |
| vs SMA20 | 1.075x | Above |
| vs SMA50 | 1.401x | Above |
| vs SMA200 | 2.613x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $70.11
- **Stop Loss:** $62.27 (11.2% risk)
- **Target:** $77.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $10,726.83
- **Portfolio %:** 10.73%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*